Results 41 to 50 of about 18,115 (178)

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells

BMC Cancer
Background Regorafenib, a multi-targeted kinase inhibitor, has been used in the treatment of Hepatocellular carcinoma (HCC). The purpose of this study is to investigate the mechanism of Regorafenib in HCC.
Yipeng Pan, Bo You, Xue Zhao, Shanxin Zhang, Wei Li   +4 more
doaj   +1 more source

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule

Frontiers in Oncology, 2023
IntroductionRegorafenib is a tyrosine kinase inhibitor (TKI) approved in metastatic gastrointestinal stromal tumor (GIST), colorectal cancer, and hepatocarcinoma.
Maria Susanna Grimaudo, Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Salvatore Lorenzo Renne, Armando Santoro, Armando Santoro, Alexia Francesca Bertuzzi   +14 more
doaj   +1 more source

Viscoelastic hydrogel potentiates cancer cell stemness and drug resistance through Piezo1‐dependent mechanotransduction

BMEMat, EarlyView.
The effects of matrix dynamics on cancer progression remain unclear. Herein, we fabricated a tunable dynamic hydrogel via reversible host–guest crosslinking and demonstrated that high matrix dynamics activate Piezo1 and its downstream PI3K/AKT and Wnt/β‐catenin signaling pathways, thereby enhancing cancer spheroid assembly, elevating cancer stemness ...
Yi Liu, Huiyao Deng, Hanlei Zhang, Chutian Huang, Huolun Feng, Xiayi Xu, Heemin Kang, Meiling Zhu, Liming Bian, Kunyu Zhang   +9 more
wiley   +1 more source

Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension

, 2021
Pulmonary hypertension (PH) is characterized by a progressive elevation of mean arterial pressure followed by right ventricular failure and death. Previous studies have indicated that numerous inhibitors of receptor tyrosine kinase signaling could be ...
Baktybek Kojonazarov, Norbert Weissmann, Ghofrani, H., Schermuly, R., Veeroju, S., Grimminger, F., Hossein Ardeschir Ghofrani, Seeger, W., Weiss, A., Astrid Weiss, Swathi Veeroju, Kojonazarov, B., Weissmann, N., Werner Seeger, Friedrich Grimminger, Tatyana Novoyatleva, Ralph Theo Schermuly, Novoyatleva, T.   +17 more
core   +1 more source

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension [PDF]

, 2018
Background and Aims: Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC).
Roderburg, Christoph, Magdaleno, Fernando, Nikolova, Ivelina, Schueller, Florian, Kristiansen, Glen, Lüdde, Tom, Ritz, Thomas, Loosen, Sven, Klein, Sabine, Uschner, Frank Erhard, Lammers, Twan, Luedde, Tom, Vucur, Michael, Trebicka, Jonel, Schierwagen, Robert, Gröschl, Stefanie   +15 more
core   +1 more source

Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures

BMC Nephrology, 2022
Background Regorafenib belongs to a sub-group of small-molecule multi-targeted tyrosine kinase inhibitors(TKIs). In various studies with respect to the side-effect of regorafenib, drug-associated proteinuria standardly qualified to be defined as ...
Qinghua Yin, Na Guo, Xueli Zhou, Huan Xu, Song Lei, Ping Fu, Hui Zhong   +6 more
doaj   +1 more source

Advances in Immunological Combination Therapy for Colorectal Cancer

iMetaMed, EarlyView.
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu, Rongbo Wen, Tianshuai Zhang, Fuao Cao, Xiaoming Zhu, Liqiang Hao, Wei Zhang, Guanyu Yu   +7 more
wiley   +1 more source

Triggering of Suicidal Erythrocyte Death by Regorafenib

, 2016
Background/Aims: The multikinase inhibitor regorafenib is utilized for the treatment of malignancy. The substance is effective in part by triggering suicidal death or apoptosis of tumor cells. Side effects of regorafenib include anemia.
Salem Abbès, Jens Zierle, Rosi Bissinger, Florian Lang, Ghada Bouguerra   +4 more
core   +1 more source

Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study

, 2021
Introduction Regorafenib, a receptor tyrosine kinase inhibitor, is a routinely used targeted agent in the current treatment of patients with refractory metastatic colorectal carcinoma (mCRC).
Kerimoglu, Ulku, Musri, Fatma Yalcin, Artac, Mehmet, Eryilmaz, Melek Karakurt, Araz, Murat, Karaagac, Mustafa   +5 more
core   +1 more source